Skip to main content

Table 2 Performance of the S5 methylation classifier, cytology, and HPV16/18 genotyping for detecting CIN2+ and CIN3+

From: Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping

 

Sensitivity (95% CI)

Specificity (95% CI)

Unadjusted PPV (95% CI)

Adjusted PPV* (95% CI)

Unadjusted NPV (95% CI)

OR (95% CI)

S5 cutoff 3.7

 CIN2+

62.0 (50.4–72.7)

73.0 (66.9–78.5)

43.4 (34.0–53.0)

20.3 (16.7–23.9)

85.2 (79.6–89.8)

4.20 (2.59–7.54)

 CIN3+

70.3 (56.7–81.8)

76.6 (70.7–81.9)

45.0 (35.0–55.3)

18.0 (14.3–21.7)

90.5 (85.0–94.2)

7.75 (4.21–14.3)

S5 cutoff 0.8

 CIN2+

86.1 (76.5–92.8)

40.1 (33.8–46.6)

32.4 (26.1–39.2)

13.8 (11.5–16.0)

89.6 (82.2–94.7)

4.14 (2.10–8.14)

 CIN3+

92.5 (91.8–97.9)

38.8 (32.9–45)

23.3 (17.8–29.6)

9.9 (8.0–11.9)

96.2 (90.6–99.0)

7.76 (3.83–21.2)

HPV16/18 and cytology for CIN2+

 HPV16/18+

63.3 (51.7–73.9)

29.1 (23.4–35.3)

22.9 (17.5–29.1)

9.0 (7.2–10.9)

70.4 (60.3–79.2)

0.71 (0.42–1.21)

 ASCUS+

57.0 (45.3–68.1)

62.4 (55.9–68.6)

33.6 (25.7–42.2)

14.4 (11.5–17.3)

81.3 (74.9–86.7)

2.20 (1.3–3.7)

 LSIL+

51.9 (40.4–63.3)

68.8 (62.5–74.6)

35.7 (26.9–45.1)

15.6 (12.3–18.8)

81.1 (75.0–86.3)

2.38 (1.42–3.99)

 HSIL+

27.8 (18.3–39.1)

95.8 (92.8–98.0)

68.8 (50.0–83.9)

42.3 (34.0–50.6)

79.9 (74.8–84.4)

8.70 (3.9–19.2)

  1. ASCUS+ atypical squamous cells of undetermined significance or worse, HSIL+ high-grade squamous intraepithelial lesion or worse, LSIL+ low-grade squamous intraepithelial lesion or worse, NEG histologically negative, CIN cervical intraepithelial neoplasia (of grades 1, 2, and 3).
  2. *Adjusted PPV = (Sn × Pr)/((Sn × Pr) + (1 − Sp ) × (1 − Pr)), where Sn is sensitivity, Sp is specificity, and Pr is the CIN2+ or CIN3+ screening prevalence in the FRIDA population-based study (10% and 6.8% respectively)